[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.] #  @DrSGraff Stephanie Graff, MD, FACP, FASCO Stephanie Graff, MD, FACP, FASCO posts on X about take the, breast cancer, ct, onc the most. They currently have XXXXXX followers and XX posts still getting attention that total XXXXXX engagements in the last XX hours. ### Engagements: XXXXXX [#](/creator/twitter::838389180484898816/interactions)  - X Week XXXXXX +3,022% - X Month XXXXXX +514% - X Months XXXXXXX -XX% - X Year XXXXXXX -XX% ### Mentions: XX [#](/creator/twitter::838389180484898816/posts_active)  - X Week XX +243% - X Month XX +433% - X Months XX -XX% - X Year XXX -XX% ### Followers: XXXXXX [#](/creator/twitter::838389180484898816/followers)  - X Week XXXXXX +0.35% - X Month XXXXXX +0.76% - X Months XXXXXX +3.40% - X Year XXXXXX +4.30% ### CreatorRank: XXXXXXX [#](/creator/twitter::838389180484898816/influencer_rank)  ### Social Influence [#](/creator/twitter::838389180484898816/influence) --- **Social category influence** [luxury brands](/list/luxury-brands) #2462 **Social topic influence** [take the](/topic/take-the) #1156, [breast cancer](/topic/breast-cancer) #284, [ct](/topic/ct) #1766, [onc](/topic/onc) 1.14%, [kicks](/topic/kicks) 1.14%, [long term](/topic/long-term) 1.14%, [pts](/topic/pts) 1.14%, [res](/topic/res) 1.14%, [mbc](/topic/mbc) 1.14%, [wt](/topic/wt) #14 **Top accounts mentioned or mentioned by** [@oncoalert](/creator/undefined) [@asco](/creator/undefined) [@brownmedicine](/creator/undefined) [@myesmo](/creator/undefined) [@brownucancer](/creator/undefined) [@erikahamilton9](/creator/undefined) [@marklewismd](/creator/undefined) [@drchoueiri](/creator/undefined) [@narjustflorezmd](/creator/undefined) [@chartnote](/creator/undefined) [@janicetnbcmets](/creator/undefined) [@hoperugo](/creator/undefined) [@curijoey](/creator/undefined) [@jasminekambojmd](/creator/undefined) [@brownunivhealth](/creator/undefined) [@jcoasco](/creator/undefined) [@ptarantinomd](/creator/undefined) [@laurabukavinamd](/creator/undefined) [@glopesmd](/creator/undefined) [@mtmdphd](/creator/undefined) ### Top Social Posts [#](/creator/twitter::838389180484898816/posts) --- Top posts by engagements in the last XX hours "Signs you may be jet lagged You are not sure if you are attending #ESMO24 or #ESMO25 🤦🏼♀" [X Link](https://x.com/DrSGraff/status/1979238751151767660) [@DrSGraff](/creator/x/DrSGraff) 2025-10-17T17:31Z 21.1K followers, 2026 engagements "Its a great day to take a survey #Oncology ONC Oncology Drug Approvals Survey" [X Link](https://x.com/DrSGraff/status/1976797400606834797) [@DrSGraff](/creator/x/DrSGraff) 2025-10-10T23:50Z 21.1K followers, XXX engagements "Dr. @FAndreMD kicks off #ESMO25 - the XX Year Celebration - at Opening Session with his presidential address. @OncoAlert @myESMO" [X Link](https://x.com/DrSGraff/status/1979127119469842870) [@DrSGraff](/creator/x/DrSGraff) 2025-10-17T10:07Z 21.1K followers, 1115 engagements "#ESMO25 by the numbers 📝2926 abstracts 📄40 publications 👥 35676 participants @myESMO @OncoAlert" [X Link](https://x.com/DrSGraff/status/1979132963938824306) [@DrSGraff](/creator/x/DrSGraff) 2025-10-17T10:30Z 21.1K followers, 1782 engagements "Long-term follow-up of #POSITIVE trial shows continued safety 71-month median follow-up supporting this model for patients desiring the opportunity to pursue pregnancy after breast cancer. #ESMO25 @OncoAlert" [X Link](https://x.com/DrSGraff/status/1979163441102233727) [@DrSGraff](/creator/x/DrSGraff) 2025-10-17T12:31Z 21.1K followers, 1497 engagements "Yay @hoperugo 🥂 #EdBook #ASCO26" [X Link](https://x.com/DrSGraff/status/1979196623180759366) [@DrSGraff](/creator/x/DrSGraff) 2025-10-17T14:43Z 21.1K followers, XXX engagements "The 🔑 take away at this time of #RIBOLARIS is XX% of patients will shift from high risk to low risk with XX weeks of neoadj letrozole + ribo; will need to understand long term outcome on clinical outcomes like distant disease free survival for example #ESMO25" [X Link](https://x.com/DrSGraff/status/1979161770804617461) [@DrSGraff](/creator/x/DrSGraff) 2025-10-17T12:25Z 21.1K followers, 1130 engagements "MonarchE adj Abemaciclib shows improved overall survival w/small absolute benefit XXX% relative benefit XXXX% at XX mos Hot take: Incremental improvement is not flashy & exciting like big curve separation but less metastatic disease & more life is good #ESMO25 @OncoAlert" [X Link](https://x.com/DrSGraff/status/1979173899423096863) [@DrSGraff](/creator/x/DrSGraff) 2025-10-17T13:13Z 21.1K followers, 1505 engagements "OptiTROP-Breast02 using Sac-TMT (a Trop2 Topo-I ADC) improves PFS HR XXXX as compared to chemotherapy #ESMO25" [X Link](https://x.com/DrSGraff/status/1979476863052329352) [@DrSGraff](/creator/x/DrSGraff) 2025-10-18T09:17Z 21.1K followers, 1787 engagements "DB05 T-DXd vs TDM1 in pts w/HER2+ RCB after neoadj. cT2N0 excded concurrent ☢ ok CT high res Q12 wks after baseline XXX% in IDFS (HR 0.47) Immature OS DRFS brain met free survival but favorable trend ❓W/shifting data for oral combos is duration & AEs acceptable #ESMO25" [X Link](https://x.com/DrSGraff/status/1979568268055855571) [@DrSGraff](/creator/x/DrSGraff) 2025-10-18T15:20Z 21.1K followers, 1393 engagements "SHR-A1811 (trastuzumab rezetecan) improved PFS vs pyrotinib + cape in 2L HER2+ MBC mPFS XXXX vs XXX mos (HR 0.22) 12-month PFS XXXX% vs XXXX% #ESMO25" [X Link](https://x.com/DrSGraff/status/1979806283613278608) [@DrSGraff](/creator/x/DrSGraff) 2025-10-19T07:06Z 21.1K followers, 4679 engagements "ASCENT-03 (1L sacitizumab vs chemo) improved mPFS for mTNBC patients not ICI candidateS mPFS XXX vs XXX mos HR XXXX Crossover allowed 🚨Use of prophylactic G-CSF is advised #ESMO25 @OncoAlert" [X Link](https://x.com/DrSGraff/status/1979817744624394347) [@DrSGraff](/creator/x/DrSGraff) 2025-10-19T07:51Z 21.1K followers, 2807 engagements "If you are excited by 1L TNBC TROP2 ADC at @myESMO TROPION-Breast05 is ✨NOW✨ enrolling PDL1 High 1L mTNBC Breast Cancer globally #ESMO25 @MOliveira_MD @curijoey @LoiSher @RebeccaDSing @OncoAlert" [X Link](https://x.com/DrSGraff/status/1979821313813590330) [@DrSGraff](/creator/x/DrSGraff) 2025-10-19T08:05Z 21.1K followers, 1241 engagements "Has there ever been a more true quote Im chronically excitedbut what Im acutely excited about @DrChoueiri outlines whats to come at #ESMO25 and highlights what so many of us are also chronically and acutely excited about @myESMO @OncoAlert" [X Link](https://x.com/DrSGraff/status/1979131810710692256) [@DrSGraff](/creator/x/DrSGraff) 2025-10-17T10:26Z 21.1K followers, 6774 engagements "NATALEE Adj Ribo shows sustained improvement in IDFS. Hot take (the dreaded cross trial comparison): NATALEE is a lower risk population so that long slow follow-up is critical with XX% of HR+ recurrences happening X years and that OS trend is promising. #ESMO24 @OncoAlert" [X Link](https://x.com/DrSGraff/status/1979175936332316869) [@DrSGraff](/creator/x/DrSGraff) 2025-10-17T13:21Z 21.1K followers, 6585 engagements "Although giredestrant + everolimus showed improved PFS in both mutESR1 and ITT (wt and mutESR1) an exploratory analysis suggests that the mutESR1 population is driving the benefit in the ITT group with no difference in PFS for the wt subgroup analysis. #ESMO25 @OncoAlert" [X Link](https://x.com/DrSGraff/status/1979465058502451482) [@DrSGraff](/creator/x/DrSGraff) 2025-10-18T08:30Z 21.1K followers, 5282 engagements "VIKTORIA-1 w PI3K/AKT/mTOR (PAM) pathway Inhibitor gedatolisib + fulvestrant +/- palbo improves PFS in WT as triplet & doublet w/different AEsstomatitis hyperglycemia But it is IV. Weekly. With inavo capi alpeli + many 2L oralswhere do we need geda #ESMO25 @OncoAlert" [X Link](https://x.com/DrSGraff/status/1979491524007121283) [@DrSGraff](/creator/x/DrSGraff) 2025-10-18T10:15Z 21.1K followers, 13.3K engagements "DB11 NeoAdj TDxdx4 THPx4 for HER2+ BC pCR XXXX% (🔺11.2% vs DD AC THP); PCR HR+ XXXX% HRneg XXXX% Reasonable safety but incld Q6 wk high-res CT wh/is clinical challenge ❓With consolidative tx (TDXdpalbo tucatinib TDM1) does everyone needs upfront#ESMO25 @OncoAlert" [X Link](https://x.com/DrSGraff/status/1979560902295978292) [@DrSGraff](/creator/x/DrSGraff) 2025-10-18T14:51Z 21.1K followers, 1367 engagements "Destiny Breast XX updates by subgroups show (as per prior forest plots) all subgroups benefit. Given opportunity for therapeutic interventions HR+ and mut PIK3 are of particular interest #ESMO25" [X Link](https://x.com/DrSGraff/status/1979802462841454972) [@DrSGraff](/creator/x/DrSGraff) 2025-10-19T06:51Z 21.1K followers, XXX engagements "TROPION-Breast02 TROPION-Breast02 improves OS and PFS over chemotherapy in 1L MTNBC not eligible for ICI. OS HR XXXX XXXX mos mOS PFS HR XXXX XXXX mos mPFS #ESMO25 introduces a new standard of care pending regulatory approval @OncoAlert" [X Link](https://x.com/DrSGraff/status/1979819618819780664) [@DrSGraff](/creator/x/DrSGraff) 2025-10-19T07:59Z 21.1K followers, 1250 engagements "Both vepdegestrant (TACTIVE-N) and giredrestrant (EMPRESS) are neoadj window of opportunity trials to explore biomarkers and demonstrate that these two novel ETs ***DO THE THINGS*** (Okay thats the cliff notes versionbut its X after all) #ESMO25 @OncoAlert" [X Link](https://x.com/DrSGraff/status/1979836924669157597) [@DrSGraff](/creator/x/DrSGraff) 2025-10-19T09:08Z 21.1K followers, 1691 engagements "BEGONIA arm X & X show excellent ORR & DOR for Dato-DXd. #ESMO25" [X Link](https://x.com/DrSGraff/status/1980215666897826142) [@DrSGraff](/creator/x/DrSGraff) 2025-10-20T10:13Z 21.1K followers, XXX engagements
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
@DrSGraff Stephanie Graff, MD, FACP, FASCO
Stephanie Graff, MD, FACP, FASCO posts on X about take the, breast cancer, ct, onc the most. They currently have XXXXXX followers and XX posts still getting attention that total XXXXXX engagements in the last XX hours.
Engagements: XXXXXX #
- X Week XXXXXX +3,022%
- X Month XXXXXX +514%
- X Months XXXXXXX -XX%
- X Year XXXXXXX -XX%
Mentions: XX #
- X Week XX +243%
- X Month XX +433%
- X Months XX -XX%
- X Year XXX -XX%
Followers: XXXXXX #
- X Week XXXXXX +0.35%
- X Month XXXXXX +0.76%
- X Months XXXXXX +3.40%
- X Year XXXXXX +4.30%
CreatorRank: XXXXXXX #
Social Influence #
Social category influence luxury brands #2462
Social topic influence take the #1156, breast cancer #284, ct #1766, onc 1.14%, kicks 1.14%, long term 1.14%, pts 1.14%, res 1.14%, mbc 1.14%, wt #14
Top accounts mentioned or mentioned by @oncoalert @asco @brownmedicine @myesmo @brownucancer @erikahamilton9 @marklewismd @drchoueiri @narjustflorezmd @chartnote @janicetnbcmets @hoperugo @curijoey @jasminekambojmd @brownunivhealth @jcoasco @ptarantinomd @laurabukavinamd @glopesmd @mtmdphd
Top Social Posts #
Top posts by engagements in the last XX hours
"Signs you may be jet lagged You are not sure if you are attending #ESMO24 or #ESMO25 🤦🏼♀"
X Link @DrSGraff 2025-10-17T17:31Z 21.1K followers, 2026 engagements
"Its a great day to take a survey #Oncology ONC Oncology Drug Approvals Survey"
X Link @DrSGraff 2025-10-10T23:50Z 21.1K followers, XXX engagements
"Dr. @FAndreMD kicks off #ESMO25 - the XX Year Celebration - at Opening Session with his presidential address. @OncoAlert @myESMO"
X Link @DrSGraff 2025-10-17T10:07Z 21.1K followers, 1115 engagements
"#ESMO25 by the numbers 📝2926 abstracts 📄40 publications 👥 35676 participants @myESMO @OncoAlert"
X Link @DrSGraff 2025-10-17T10:30Z 21.1K followers, 1782 engagements
"Long-term follow-up of #POSITIVE trial shows continued safety 71-month median follow-up supporting this model for patients desiring the opportunity to pursue pregnancy after breast cancer. #ESMO25 @OncoAlert"
X Link @DrSGraff 2025-10-17T12:31Z 21.1K followers, 1497 engagements
"Yay @hoperugo 🥂 #EdBook #ASCO26"
X Link @DrSGraff 2025-10-17T14:43Z 21.1K followers, XXX engagements
"The 🔑 take away at this time of #RIBOLARIS is XX% of patients will shift from high risk to low risk with XX weeks of neoadj letrozole + ribo; will need to understand long term outcome on clinical outcomes like distant disease free survival for example #ESMO25"
X Link @DrSGraff 2025-10-17T12:25Z 21.1K followers, 1130 engagements
"MonarchE adj Abemaciclib shows improved overall survival w/small absolute benefit XXX% relative benefit XXXX% at XX mos Hot take: Incremental improvement is not flashy & exciting like big curve separation but less metastatic disease & more life is good #ESMO25 @OncoAlert"
X Link @DrSGraff 2025-10-17T13:13Z 21.1K followers, 1505 engagements
"OptiTROP-Breast02 using Sac-TMT (a Trop2 Topo-I ADC) improves PFS HR XXXX as compared to chemotherapy #ESMO25"
X Link @DrSGraff 2025-10-18T09:17Z 21.1K followers, 1787 engagements
"DB05 T-DXd vs TDM1 in pts w/HER2+ RCB after neoadj. cT2N0 excded concurrent ☢ ok CT high res Q12 wks after baseline XXX% in IDFS (HR 0.47) Immature OS DRFS brain met free survival but favorable trend ❓W/shifting data for oral combos is duration & AEs acceptable #ESMO25"
X Link @DrSGraff 2025-10-18T15:20Z 21.1K followers, 1393 engagements
"SHR-A1811 (trastuzumab rezetecan) improved PFS vs pyrotinib + cape in 2L HER2+ MBC mPFS XXXX vs XXX mos (HR 0.22) 12-month PFS XXXX% vs XXXX% #ESMO25"
X Link @DrSGraff 2025-10-19T07:06Z 21.1K followers, 4679 engagements
"ASCENT-03 (1L sacitizumab vs chemo) improved mPFS for mTNBC patients not ICI candidateS mPFS XXX vs XXX mos HR XXXX Crossover allowed 🚨Use of prophylactic G-CSF is advised #ESMO25 @OncoAlert"
X Link @DrSGraff 2025-10-19T07:51Z 21.1K followers, 2807 engagements
"If you are excited by 1L TNBC TROP2 ADC at @myESMO TROPION-Breast05 is ✨NOW✨ enrolling PDL1 High 1L mTNBC Breast Cancer globally #ESMO25 @MOliveira_MD @curijoey @LoiSher @RebeccaDSing @OncoAlert"
X Link @DrSGraff 2025-10-19T08:05Z 21.1K followers, 1241 engagements
"Has there ever been a more true quote Im chronically excitedbut what Im acutely excited about @DrChoueiri outlines whats to come at #ESMO25 and highlights what so many of us are also chronically and acutely excited about @myESMO @OncoAlert"
X Link @DrSGraff 2025-10-17T10:26Z 21.1K followers, 6774 engagements
"NATALEE Adj Ribo shows sustained improvement in IDFS. Hot take (the dreaded cross trial comparison): NATALEE is a lower risk population so that long slow follow-up is critical with XX% of HR+ recurrences happening X years and that OS trend is promising. #ESMO24 @OncoAlert"
X Link @DrSGraff 2025-10-17T13:21Z 21.1K followers, 6585 engagements
"Although giredestrant + everolimus showed improved PFS in both mutESR1 and ITT (wt and mutESR1) an exploratory analysis suggests that the mutESR1 population is driving the benefit in the ITT group with no difference in PFS for the wt subgroup analysis. #ESMO25 @OncoAlert"
X Link @DrSGraff 2025-10-18T08:30Z 21.1K followers, 5282 engagements
"VIKTORIA-1 w PI3K/AKT/mTOR (PAM) pathway Inhibitor gedatolisib + fulvestrant +/- palbo improves PFS in WT as triplet & doublet w/different AEsstomatitis hyperglycemia But it is IV. Weekly. With inavo capi alpeli + many 2L oralswhere do we need geda #ESMO25 @OncoAlert"
X Link @DrSGraff 2025-10-18T10:15Z 21.1K followers, 13.3K engagements
"DB11 NeoAdj TDxdx4 THPx4 for HER2+ BC pCR XXXX% (🔺11.2% vs DD AC THP); PCR HR+ XXXX% HRneg XXXX% Reasonable safety but incld Q6 wk high-res CT wh/is clinical challenge ❓With consolidative tx (TDXdpalbo tucatinib TDM1) does everyone needs upfront#ESMO25 @OncoAlert"
X Link @DrSGraff 2025-10-18T14:51Z 21.1K followers, 1367 engagements
"Destiny Breast XX updates by subgroups show (as per prior forest plots) all subgroups benefit. Given opportunity for therapeutic interventions HR+ and mut PIK3 are of particular interest #ESMO25"
X Link @DrSGraff 2025-10-19T06:51Z 21.1K followers, XXX engagements
"TROPION-Breast02 TROPION-Breast02 improves OS and PFS over chemotherapy in 1L MTNBC not eligible for ICI. OS HR XXXX XXXX mos mOS PFS HR XXXX XXXX mos mPFS #ESMO25 introduces a new standard of care pending regulatory approval @OncoAlert"
X Link @DrSGraff 2025-10-19T07:59Z 21.1K followers, 1250 engagements
"Both vepdegestrant (TACTIVE-N) and giredrestrant (EMPRESS) are neoadj window of opportunity trials to explore biomarkers and demonstrate that these two novel ETs DO THE THINGS (Okay thats the cliff notes versionbut its X after all) #ESMO25 @OncoAlert"
X Link @DrSGraff 2025-10-19T09:08Z 21.1K followers, 1691 engagements
"BEGONIA arm X & X show excellent ORR & DOR for Dato-DXd. #ESMO25"
X Link @DrSGraff 2025-10-20T10:13Z 21.1K followers, XXX engagements